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CELL CULTURE ENGINEERING AND BIOSIMILARS: THE PHYSICIAN’S PERSPECTIVE 
 
Jan Hillson 
Momenta Pharmaceuticals, Inc. 
jhillson@momentapharma.com 
  
Biosimilars promise to increase access to life-saving and life-enhancing therapeutics, while creating cost 
savings that can fund further innovations in health care. Achievement of these goals is critically dependent on 
acceptance by prescribing physicians. This session will explore the following questions: What do clinicians care 
about? What do they know about the manufacture and characterization of biosimilars? What should they know? 
These questions will be addressed in the context of specific examples arising in the development of biosimilars 
to Neupogen, Infliximab, Humira, and Rituximab. 
 
